- IPC GENERAL
- Genetics, Pathophysiology, & Epidemiology, Research, Treatment
Most psoriasis treatment today targets one well-known pathway: IL-23 and IL-17. A new study published in the Journal of Experimental Medicine describes a different route: gene mutations that drive psoriasis through the body’s antiviral defense system, and it does not behave like classic psoriasis. Among the 21 patients identified with this mutation, 12 had already failed standard biologics. Nearly all of them cleared on a JAK1 or TYK2 inhibitor instead.
Who Should Read This
Dermatologists managing psoriasis patients who are not responding to IL-17 or IL-23 biologics, particularly those with early onset disease, skin pigment changes, joint or dental involvement, or flares tied to infection. Researchers working in psoriasis genetics, RNA editing, or interferonopathies will also want the mechanistic detail below.
What ADAR1 Normally Does
ADAR1 edits the body’s own RNA as well as exogenous viral RNA, so the immune system is not constantly activated. When ADAR1 is not working, the immune system behaves as if an infection is underway, keeping interferon signaling switched on and driving constant inflammation.
What They Found
Four multiplex families with early-onset plaque psoriasis carried heterozygous ADAR1 mutations that segregated with disease. A follow-up screen of 125 additional patients identified more variants, totaling 21 patients.
These patients showed a distinct pattern: elevated interferon activity in blood and skin, overlap with features of Singleton-Merten syndrome (joint disease, dental problems, arterial calcification), and skin pigment changes. Lab studies in keratinocytes and melanocytes confirmed the mechanism: reduced ADAR1 function boosted interferon-stimulated genes and substantially reduced RNA editing.
One surprise: melanocytes and keratinocytes, not just plasmacytoid dendritic cells, were a major source of the interferon signature. pDCs stayed at normal levels in these lesions.
Why It Matters Clinically
Standard biologics target IL-17 and IL-23. This subtype does not run on that axis, which is likely why 12 of the 21 ADAR1-mutant patients did not respond adequately to them despite multiple lines of therapy. Nearly all cleared or nearly cleared on upadacitinib (a JAK1 inhibitor) or deucravacitinib (a TYK2 inhibitor) instead, including patients with concurrent psoriatic arthritis or ankylosing spondylitis.
"Our research establishes for the first time the pathogenicity in chronic plaque psoriasis of inborn errors affecting the ADAR1 RNA editing-MDA5-Type I Interferon (IFN) axis. With two other independent high-profile publications reporting, this time at the RNA level, similar conclusions at the population scale, our findings pave the way for precision medical approaches in psoriasis and in other immune-mediated and inflammatory diseases, allowing us to reach optimal long-term outcomes in a larger proportion of patients."
Hervé Bachelez, MD, PhD
Senior author of the study; IPC Past President
What To Do With This
If a patient in your practice matches this profile (treatment-resistant psoriasis with early onset, pigment changes, or infection-triggered flares), this study may offer a missing piece of the puzzle. Genetic testing for ADAR1 is not yet standard practice, but that may change as more cases are documented in the literature.
Reference
Assan F, Tragin M, Marella S, et al. ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype. J Exp Med. 2026;223(9):e20260054.
